FDA and EMA Grant Orphan Drug Designation to CPI-008 for Pancreatic Cancer Surgical Imaging
核心洞察
The FDA and European Medicines Agency have granted orphan drug designation to CPI-008 (搜索) (cRGD-ZW800-1), a novel integrin (搜索)-targeted imaging agent designed to enhance margin detection during pancreatic cancer (搜索) surgery.
CPI-008 (搜索) demonstrated strong imaging capabilities in the phase 2 FLUOPANC study, which evaluated the agent's feasibility across different doses for visualizing pancreatic tumors during surgical resection.
The orphan drug designation provides valuable development incentives including fee exemptions, tax credits, and potential market exclusivity of up to 7 years in the US and 10 years in Europe.
Curadel Pharma (搜索) announced that its novel imaging agent CPI-008 (搜索) (cRGD-ZW800-1) has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use in margin detection of pancreatic cancer (搜索) during surgery. The integrin (搜索)-targeted, zwitterionic imaging drug is designed to enhance surgeons' ability to accurately visualize cancerous cells, potentially optimizing surgical outcomes for patients with pancreatic cancer and select other tumors.
"Receiving orphan designation from both the FDA and the EMA is a profoundly important milestone for Curadel, granting us valuable incentives to fuel our development efforts," said John V. Frangioni, MD, PhD, founder and chief executive officer of Curadel Pharma (搜索). "As a pioneering company working to introduce significant advances in surgical imaging, the efficiencies of fee exemptions, credits, along with the potential for market exclusivity are vital tools to help us smartly deploy our resources and focus on delivering value to the surgical community."
Regulatory Benefits and Market Exclusivity
The FDA grants orphan drug designation to therapeutic candidates for conditions affecting fewer than 200,000 people in the United States. This designation provides significant development incentives including exemption from user fees, tax credits for qualified clinical trials, and potential for up to seven years of U.S. market exclusivity if the product receives approval for its designated indication.
Similarly, the EMA's orphan designation includes protocol assistance, reduced regulatory fees, potential for early access conditional approvals, and market exclusivity of up to 10 years if approved. These regulatory advantages are particularly valuable for companies developing treatments for rare diseases like pancreatic cancer (搜索).
Clinical Evidence from FLUOPANC Study
CPI-008 (搜索) has been evaluated in multiple phase 2 clinical trials, with initial focus on its use during the resection of pancreatic, biliary, and head and neck tumors (搜索). The agent displayed strong imaging capabilities in pancreatic cancer (搜索) in the phase 2 FLUOPANC study (NCT05518071).
The FLUOPANC trial was a single-center study conducted at Leiden University Medical Center in the Netherlands, designed to evaluate the feasibility of CPI-008 (搜索) across a range of doses. The open-label study featured a 2-factorial design with a goal of enrolling 20 patients with malignant pancreatic or distal/hilar bile duct tumors eligible for surgical resection.
The study included four dose-finding cohorts plus a fifth expansion cohort. Patients received a single infusion of CPI-008 (搜索) at either 0.05 mg/kg or 0.025 mg/kg, administered either 2 to 4 hours or 14 to 24 hours prior to surgical intervention. During surgery, assessments included near-infrared (NIR) fluorescence imaging of tumor, lymph nodes, possible distant metastasis, and anatomical related structures.
Study Design and Endpoints
The study's primary endpoint was the visualization of the primary tumor via CPI-008 (搜索) and NIR-fluorescence imaging, with visualization measured using the tumor-to-background (TBR) ratio both in vivo and ex vivo. A TBR of at least 1.5 was determined to be the cut-off value, providing sufficient contrast for adequate visualization and delineation.
Secondary endpoints included the incidence and severity of adverse effects, concordance between clinical assessment and histopathological examination with NIR-fluorescence imaging results, determining the optimal dose and dose interval of CPI-008 (搜索), tumor positive margins detected with NIR fluorescence imaging, and the number of tumor-positive lymph nodes and metastases detected by NIR fluorescence imaging.
Addressing Unmet Medical Need
Pancreatic cancer (搜索) remains one of the most challenging cancers to treat, and current imaging tools are not fully effective in helping to identify the full extent of cancerous cells to allow for complete removal during surgical procedures. By enhancing surgeons' ability to accurately visualize cancerous cells, Curadel's technology could become an important asset in the surgical suite to optimize outcomes not only for pancreatic cancer patients, but potentially for other tumor types as well.
The company's zwitterionic imaging technology represents a novel approach to intraoperative tumor detection, potentially addressing significant limitations in current surgical imaging capabilities for pancreatic cancer (搜索) resection procedures.